Received: 19 September 2016 | Revised: 2 November 2016 | Accepted: 3 November 2016

DOI: 10.1002/pbc.26377

LETTER TO THE EDITOR

WILEY Pediatric Blood & Cancer

SIOP INTERNATIONAL SOCIETY OF PAEDIATRIC ONCOLOGY

aspho The American Society of Pediatric Hematology/Oncology

A case of advanced infantile myofibromatosis harboring a novel MYH10-RET fusion

1 | INTRODUCTION

To the Editor: Infantile myofibromatosis (IM), predominantly observed in infants and young children, features variable prognosis, as evidenced by some tumors spontaneously regressing, others successfully surgically managed, and those multifocal or with visceral involvement requiring systemic therapy.[1–3] For patients with unresectable, persistent, and disseminated IM, comprehensive genomic profiling (CGP) may identify targetable genomic alterations. In this case of a child with a single focus unresectable IM, CGP identified a novel *MYH10-RET* fusion, suggesting possible utility of RET-targeted therapies.

2 | RESULTS

The index patient is a newborn female with a large mass in the left sacrum and inability to move lower extremities. Magnetic resonance imaging revealed a single large multilobulated retroperitoneal mass encasing the lumbosacral spine, with a portion of the mass within the lumbosacral spinal canal and multiple neural foramina bilaterally. This mass encased multiple vessels and narrowed the iliac veins bilaterally and the inferior vena cava. Surgical resection was deemed unfeasible.

Biopsy revealed a moderately cellular lesion composed of spindle cells with a fascicular architecture and some areas displaying prominent hemangiopericytomatous vascular pattern with adipose tissue infiltration. Patchy extramedullary hematopoiesis and focal intervascular extension by the tumor were noted. CD34, HHF35, desmin, and myogenin were negative, whereas smooth muscle actin was focally and weakly positive. Based on these features and fluorescence in situ hybridization (FISH) negativity for the t(12;15)(p13;q25) *ETV6-NTRK3* translocation, the diagnosis was a low-grade spindle cell tumor consistent with IM.

Initial treatment with vincristine, actinomycin-D, and cyclophosphamide was poorly tolerated, leading to necrotizing enterocolitis, liver dysfunction, and venoocclusive disease. Subsequent weekly vinblastine and methotrexate (VBL/MTZ) were well tolerated—after 26 weeks, tumor shrunk by ~40%, and neurologic function of extremities and urinary continence improved. Currently at 42 weeks on VBL/MTZ, she is continuing to respond. CGP of the tumor revealed a single alteration, a *MYH10-RET* fusion (Fig. 1).



FIGURE 1 Identification of a *MYH10-RET* fusion in the soft tissue myofibromatosis. A rearrangement between the *MYH10* and *RET* loci resulted in a MYH10-RET fusion protein that is predicted to include the MYH10 myosin motor, IQ domain, and a portion of the coiled-coil domain, as well as the entire kinase domain of RET

3 | DISCUSSION

This is the first report describing a *RET* fusion in IM. In lung and thyroid carcinomas, *RET* fusions are established oncogenic drivers, sensitive to RET inhibitors.[4,5] *MYH10-RET*, although novel, has the same domain structure as the well-characterized *KIF5B-RET*, indicating that this fusion is an oncogenic driver.

This finding also suggests broadening of diagnostic possibilities. Previously, familial IM has been associated with mutations of *PDGFRB*.[6,7] Kinase fusions, particularly involving *ALK*, but also *ROS1*, *PDGFRB*, and *RET*, are observed in a related entity, inflammatory myofibroblastic tumor (IMT). The differential diagnosis for this lesion does include IMT, and morphologic and immunohistochemical features of both entities do overlap. Since *RET* alterations have never previously been observed in IM but have been observed in IMT, it is possible that this lesion might be characterized as an IMT under other circumstances.[8] Importantly, IMTs harboring various kinase fusions, including *ALK* and *ROS1*, were sensitive to small molecule kinase inhibitors.[9,10]

For this child, identification of the *MYH10-RET* fusion indicates possible benefit from RET inhibitors. Further, CGP myofibromatosis and IMT should reveal whether *RET* fusions are a recurrent feature of aggressive myofibromatosis or whether the index case is genomically unique and may be better characterized as an IMT.

CONFLICT OF INTEREST

M.R., S.M.A., A.B.S., A.H., S.M., Y.C., R.L.E., P.J.S., J.S.R., and V.A.M. are employees and stockholders of Foundation Medicine, Inc. T.W.L. is supported by an NIH grant R01 CA199937, as well as by Children's Health; he is a consultant for Novartis and LOXO Oncology. For the remaining authors, no sources of funding or potential conflicts of interest were declared.

Abbreviations: CGP, comprehensive genomic profiling; FISH, fluorescence in situ hybridization; IM, infantile myofibromatosis; IMT, inflammatory myofibroblastic tumor; MTZ, methotrexate; VBL, vinblastine

Mark Rosenzweig and Siraj M. Ali
Foundation Medicine, Inc., Cambridge, Massachusetts

Victor Wong
Rady Children's Hospital, San Diego, California and University of California San Diego, San Diego, California

Alexa B. Schrock
Foundation Medicine, Inc., Cambridge, Massachusetts

Theodore W. Laetsch
University of Texas Southwestern Medical Center/Children's Health, Dallas, Texas

William Ahrens
Zhejiang University International Hospital, Hangzhou, China

Andreas Heilmann, Samantha Morley, Yakov Chudnovsky and Rachel L. Erlich
Foundation Medicine, Inc., Cambridge, Massachusetts

Kai Wang
Zhejiang University International Hospital, Hangzhou, China

Philip J. Stephens
Foundation Medicine, Inc., Cambridge, Massachusetts

Jeffrey S. Ross
Albany Medical Center, Albany, New York and Foundation Medicine, Inc., Cambridge, Massachusetts

Vincent A. Miller
Foundation Medicine, Inc., Cambridge, Massachusetts

Javier Oesterheld
Levine Pediatric Hematology/Oncology, Levine Children's Hospital, Charlotte, North Carolina

Correspondence
Mark Rosenzweig, Foundation Medicine, Inc., 150 Second Street, 1st Floor, Cambridge, MA 02141.
***Email**: mrosenzweig@foundationmedicine.com*

Javier Oesterheld, Levine Pediatric Hematology/Oncology, 1001 Blythe Boulevard, Suite 601, Charlotte, NC 28203.
***Email**: Javier.oesterheld@carolinashealthcare.org*

REFERENCES

1. Levine E, Freneaux P, Schleiermacher G, et al. Risk-adapted therapy for infantile myofibromatosis in children. *Pediatr Blood Cancer*. 2012;59(1):115–120.
2. Weaver MS, Navid F, Huppmann A, Meany H, Angiolillo A. Vincristine and dactinomycin in infantile myofibromatosis with a review of treatment options. *J Pediatr Hematol Oncol*. 2015;37(3):237–241.
3. Wu SY, McCavit TL, Cederberg K, Galindo RL, Leavey PJ. Chemotherapy for generalized infantile myofibromatosis with visceral involvement. *J Pediatr Hematol Oncol*. 2015;37(5):402–405.
4. Drilon A, Wang L, Hasanovic A, et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. *Cancer Discov*. 2013;3(6):630–635.
5. Falchook GS, Ordonez NG, Bastida CC, et al. Effect of the RET Inhibitor vandetanib in a patient with RET fusion-positive metastatic non-small-cell lung cancer. *J Clin Oncol*. 2016;34(15):e141–e144.
6. Martignetti JA, Tian L, Li D, et al. Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis. *Am J Hum Genet*. 2013;92(6):1001–1007.
7. Cheung YH, Gayden T, Campeau PM, et al. A recurrent PDGFRB mutation causes familial infantile myofibromatosis. *Am J Hum Genet*. 2013;92(6):996–1000.
8. Coffin CM, Alaggio R, Dehner LP. Some general considerations about the clinicopathologic aspects of soft tissue tumors in children and adolescents. *Pediatr Dev Pathol*. 2012;15(1 Suppl):11–25.
9. Lovly CM, Gupta A, Lipson D, et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. *Cancer Discov*. 2014;4(8):889–895.
10. Subbiah V, McMahon C, Patel S, et al. STUMP un"stumped": antitumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. *J Hematol Oncol*. 2015;8:66.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.